-
201
The Feasibility of Whole-Liver Drainage with a Novel 8 mm Fully Covered Self-Expandable Metal Stent Possessing an Ultra-Slim Introducer for Malignant Hilar Biliary Obstructions
Published 2022-10-01“…In this article, the results of whole-liver drainage tests using this novel FCSEMS for MHBO are reported. Methods: Unresectable MHBOs up to Bismuth IIIa with strictures limited to the secondary branches were eligible. …”
Get full text
Article -
202
-
203
-
204
Construction and validation of a novel prognostic model for intrahepatic cholangiocarcinoma based on a combined scoring system of systemic immune-inflammation index and albumin-bil...
Published 2023-09-01“…Evaluation of the model’s predictive strength was performed through ROC survival curves and calibration curves in the training set and validation set, revealing favorable predictive performance.ConclusionThe SII+ALBI grade, a novel classification based on inflammatory and immune status, serves as a reliable prognostic indicator for postoperative OS and RFS in patients with ICC.…”
Get full text
Article -
205
-
206
-
207
Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring
Published 2023-04-01“…In this study, we introduce the Tumor Area Positivity (TAP) score, which is a novel, straightforward method for scoring tumor cells and immune cells together using visual estimation. …”
Get full text
Article -
208
Adjunct role of potassium-rich vegetarian diet and a novel potassium food supplement to improve pain in chronic rheumatoid arthritis on supervised standard care: a randomised contr...
Get full text
Article -
209
-
210
Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-...
Published 2023-05-01“…We conducted a clinical study to explore the efficacy and feasibility of a novel induction therapy with orally administered apatinib and S-1 in LA-HNSCC.Materials and methodsThis nonrandomized, single-arm, prospective clinical trial included patients with LA-HNSCCs. …”
Get full text
Article -
211
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
Published 2023-05-01“…Sera from 31 metastatic NSCLC patients, eligible for anti-PD-1/PD-L1 or combined chemoimmunotherapy, were collected prior to treatment. …”
Get full text
Article -
212
Novel care pathway to optimise antimicrobial prescribing for uncomplicated community-acquired pneumonia: study protocol for a prospective before–after cohort study in the emergency...
Published 2022-11-01“…In the intervention (after) phase, eligible participants will be managed as per the novel care pathway. …”
Get full text
Article -
213
Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator con...
Published 2021-11-01“…Objectives To establish a noninferiority of a novel three-dose recombinant rabies G protein vaccine to be administered as simulated postexposure prophylaxis when compared to five-dose WHO prequalified vaccine for better safety and immunogenicity. …”
Get full text
Article -
214
The impact of not having a primary care provider on emergency department utilization and hospitalizations before and during COVID-19: A novel retrospective cohort study linking pri...
Published 2022-08-01“…During the study period, 100,867 primary care-eligible Nova Scotians (10.1% of the population) were on the waitlist. …”
Get full text
Article -
215
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-lab...
Published 2024-03-01“…Methods The REFRACT trial is an investigator-initiated, UK National Cancer Research Institute, open-label, multi-centre, randomised phase II platform trial aimed at accelerating clinical development of novel therapies by addressing evidence gaps. The first of the three sequential novel therapy arms is epcoritamab plus lenalidomide, to be compared with investigator choice standard therapy (ICT). …”
Get full text
Article -
216
-
217
-
218
-
219
-
220